Allecra Therapeutic GmbH aims to develop a broad-spectrum solution to multidrug-resistant Gram-negative bacteria. The company will advance at least two preclinical compounds acquired from Orchid Chemicals & Pharmaceuticals Ltd., an Indian pharma, for a range of nosocomial infections.

Allecra raised €15 million ($19.6 million) in a series A round in April co-led by Edmond de Rothschild Investment Partners and Forbion Capital Partners, with participation by Orchid, EMBL Ventures and CEO Nicholas Benedict.